Illumina (NASDAQ:ILMN) Stock: Insider Keith Meister Sells 62,691 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 62,691 shares of Illumina stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $215.48, for a total transaction of $13,508,656.68. Following the completion of the transaction, the director directly owned 307,659 shares in the company, valued at approximately $66,294,361.32. This trade represents a 16.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Illumina Stock Performance

Shares of ILMN stock opened at $207.01 on Friday. The firm has a market cap of $31.30 billion, a P/E ratio of 39.91, a PEG ratio of 2.84 and a beta of 1.46. The stock’s 50-day moving average is $249.02 and its two-hundred day moving average is $179.64. Illumina, Inc. has a fifty-two week low of $112.65 and a fifty-two week high of $309.35. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same period last year, the business posted $1.34 EPS. Illumina’s revenue was up 4.2% compared to the same quarter last year. Analysts predict that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Weiss Ratings raised shares of Illumina from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday, November 2nd. Barclays increased their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a report on Wednesday, October 7th. Piper Sandler upped their price target on shares of Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. Guggenheim raised their price target on Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Finally, UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $135.00 to $260.00 in a research report on Wednesday, September 9th. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Illumina has an average rating of “Hold” and a consensus target price of $244.24.

Illumina News Roundup

Here’s some of the latest news about ILMN:

• Positive Sentiment: Illumina expanded its molecular residual disease research portfolio with a duplex-sequencing workflow and was selected to provide whole-genome sequencing for Singapore’s SG-INSIGHT study, supporting its clinical oncology and precision-medicine ambitions. Illumina Unveils Duplex Sequencing Workflow for MRD Research
• Neutral Sentiment: Analyst views remain divided, with ratings ranging from Sell to Buy. The reported consensus target is $244.24, while estimates reflect competing expectations for clinical demand and AI-related opportunities versus execution and valuation risks. Analyst Debate on Illumina’s Growth Outlook
• Negative Sentiment: Director Keith Meister sold 280,091 shares for approximately $61.1 million across November 9–11, cutting his direct stake substantially. The scale of the sales could concern investors, although he retained a sizable holding. SEC filing

Hedge Funds Weigh In On Illumina

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. E Fund Management Hong Kong Co. Ltd. bought a new position in shares of Illumina during the third quarter worth about $31,000. Signature Equity Partners LLC grew its holdings in Illumina by 246.5% in the third quarter. Signature Equity Partners LLC now owns 149 shares of the life sciences company’s stock worth $41,000 after purchasing an additional 106 shares during the period. Fiduciary Financial Advisors bought a new stake in Illumina in the second quarter valued at $26,000. MCF Advisors LLC increased its stake in Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 100 shares in the last quarter. Finally, Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina during the second quarter valued at about $32,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.